Amylyx Pharmaceuticals (AMLX) Change in Interest Receivables (2021 - 2025)
Amylyx Pharmaceuticals (AMLX) posted quarterly Change in Interest Receivables of -$6000.0 for Q4 2025, up 89.29% year-over-year from -$3169.8 in Q4 2024, and down 110.91% quarter-over-quarter from $55000.0 in Q3 2025.
Amylyx Pharmaceuticals (AMLX) Change in Interest Receivables (2021 - 2025) Analysis & Trends
Amylyx Pharmaceuticals' Change in Interest Receivables history runs 5 years deep, the most recent figure standing at -$6000.0 for Q4 2025.
- In Q4 2025, Change in Interest Receivables rose 89.29% year-over-year to -$6000.0; the TTM figure through Dec 2025 stood at -$24000.0 (up 93.31% YoY), while the FY2025 annual figure was -$24000.0, up 93.31% from the prior year.
- Change in Interest Receivables for Q4 2025 stood at -$6000.0, down from $55000.0 in the prior quarter.
- The five-year high for Change in Interest Receivables was $609000.0 in Q2 2023, with the low at -$726000.0 in Q3 2023.
- The 5-year median for Change in Interest Receivables is -$6000.0 (2025), against an average of -$52411.8.
- Peak annual rise in Change in Interest Receivables reached 4975.0% in 2023, while the deepest fall reached 25400.0% in 2023.
- Amylyx Pharmaceuticals' Change in Interest Receivables stood at $2000.0 in 2021, then plunged by 27500.0% to -$548000.0 in 2022, then surged by 163.32% to $347000.0 in 2023, then slumped by 116.14% to -$56000.0 in 2024, then surged by 89.29% to -$6000.0 in 2025.
- Business Quant data shows AMLX's Change in Interest Receivables at -$6000.0 in Q4 2025, $55000.0 in Q3 2025, and -$7000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6,000.00 |
| Sep 30, 2025 | 55,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Mar 31, 2025 | -66,000.00 |
| Dec 31, 2024 | -56,000.00 |
| Sep 30, 2024 | 118,000.00 |
| Jun 30, 2024 | -304,000.00 |
| Mar 31, 2024 | -117,000.00 |
| Dec 31, 2023 | 347,000.00 |
| Sep 30, 2023 | -726,000.00 |
| Jun 30, 2023 | 609,000.00 |
| Mar 31, 2023 | -253,000.00 |
| Dec 31, 2022 | -548,000.00 |
| Sep 30, 2022 | 48,000.00 |
| Jun 30, 2022 | 12,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Mar 31, 2021 | 2,000.00 |